# Safety and Tolerability of CMAB017 In Patients With Advanced Solid Tumors

> **NCT06933069** · PHASE1 · RECRUITING · sponsor: **Taizhou Mabtech Pharmaceutical Co.,Ltd** · enrollment: 55 (estimated)

## Conditions studied

- Solid Malignancies

## Interventions

- **DRUG:** CMAB017

## Key facts

- **NCT ID:** NCT06933069
- **Lead sponsor:** Taizhou Mabtech Pharmaceutical Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-09
- **Primary completion:** 2026-05-31
- **Final completion:** 2026-05-31
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06933069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06933069, "Safety and Tolerability of CMAB017 In Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06933069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*